Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Long-Term Investments (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Long-Term Investments for 12 consecutive years, with $310.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Investments fell 51.43% year-over-year to $310.0 million, compared with a TTM value of $310.0 million through Dec 2025, down 51.43%, and an annual FY2025 reading of $310.0 million, down 51.43% over the prior year.
  • Long-Term Investments was $310.0 million for Q4 2025 at Agios Pharmaceuticals, up from $304.3 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $655.9 million in Q3 2024 and bottomed at $21.6 million in Q1 2021.
  • Average Long-Term Investments over 5 years is $271.5 million, with a median of $269.1 million recorded in 2021.
  • The sharpest move saw Long-Term Investments tumbled 90.62% in 2023, then skyrocketed 2068.58% in 2024.
  • Year by year, Long-Term Investments stood at $266.4 million in 2021, then rose by 17.83% to $313.9 million in 2022, then crashed by 90.62% to $29.4 million in 2023, then surged by 2068.58% to $638.3 million in 2024, then plummeted by 51.43% to $310.0 million in 2025.
  • Business Quant data shows Long-Term Investments for AGIO at $310.0 million in Q4 2025, $304.3 million in Q3 2025, and $400.5 million in Q2 2025.